as they define it -a tempera ture rising above 38.3°C (101°F) on several occasions over a peri od of more than 3 weeks, for which no diagnosis has been reached despite 1 week of inpa tient investigation -is con sidered classic FUO. In the past 60 years, clinicianscientists have tracked the changing causes of these problematic fevers, as dis ease patterns and definitions have changed and as improved serologic and imaging technolo gies have begun revealing diag noses more quickly. The standard definition of FUO no longer in cludes the requirement for a week of inpatient evaluation. And in the early 1990s, Durack and Street proposed dividing FUOs into four groups: classic, nosocomial, neu tropenic, and HIVassociated. 2 According to Petersdorf and Beeson's original report, FUOs were caused by infection (in 36% of patients), malignancy (19%), collagen vascular diseases (19%), and miscellaneous other causes (19%), such as drug fever. Generally, before I evaluate the patient, many diagnostic studies have been done. Nevertheless, de termining the cause of a fever and which antibiotics to prescribe is frequently daunting. Although these fevers would be considered nosocomial by Durack and Street and may be of infectious origin, the differential diagnosis extends well beyond the usual infectious suspects. In fact, I wonder whether these are FUOs or fevers of too many origins (FTMOs).
Decisions about which other or repeat diagnostic evaluations and procedures to undertake, whether to treat empirically for C. difficile (if that isn't already be ing done), and whether to expand the antibiotic potpourri or per haps discontinue antibiotics are not easy. The nuances and com plexity of decisions regarding anti biotics are also affected by the dissonant messages bombarding physicians: the mantra that anti biotics must be used sparingly to avoid creating antibioticresistant bacteria versus the urgency to start antibiotics earlier while en suring they are the "appropriate" choices (translated as "broad," given the resistance patterns in many ICUs). When patients have been hospitalized for many months and have received numerous anti biotics but have persistent fevers, it can be unclear whether appro priate antibiotics exist or are warranted. Although some phy sicians sing CRP's praises, the neardaily variation in this mea sure and its nonspecificity make it difficult to use to guide treat ment decisions. Certainly, neither CRP levels nor procalcitonin levels help determine which cultures should be addressed with treat ment. Moreover, if one chooses to use antibiotics, the question of which of the multiple bacterial isolates need to be covered is complex.
As the keeper of the antibiot ics, should I be a conservative or a cowboy? Should the current anti biotics be continued, changed, or stopped? If there are no pre scribed antibiotics, should I rec ommend some? These are inter esting questions in the abstract, but there is a real patient suffer ing, a family with questions, and medical teams awaiting my opin ion. There are no evidencebased studies and there is no guidance on which potential source of fe ver is the single appropriate one to treat. Frequently, the treat ment approach is like playing WhacAMole: positive cultures are treated sequentially -pneu monia, then catheter cultures, then urine cultures. When the fever persists, the cycle begins again. The medical team members may be frustrated or believe they've exhausted the workup studies, and they may prefer not to order any more. They may not be too keen on continuing the same antibiotics. The ICU team hungers for something new and preferably simple. As I review the differential diagnosis, with dis claimers as to why any given di agnosis does or does not ade quately explain the fever, I get a feeling of déjà vu. The team has heard these ruminations from me and my colleagues many times, and I suspect that by now the discussion is minimally compel ling or interesting academically. This is not the multidimen sional "great case" that FUOs were once advertised to be -the cases presented on chiefofser vice rounds in which an expert diagnostician pontificates about the differential diagnosis of rare or subtle disease complexes and their presentations. Given the na ture of the illness in many of these patients, the conferences are more likely to be family con ferences that include plans for palliative care. If the old FUOs were sometimes exhilarating, the FTMOs can be debilitating. Al though some patients will recover and be discharged to lead full and active lives, many will either die or be sent to a longterm care facility.
We debate whether using anti biotics in apparently futile situa tions is ethical. After all, we may "create" some extremely resistant bacteria in one patient that could be transmitted to others. Alter natively, antibiotics may be life saving. There are few directives, ethical guidelines, or clinical path ways to follow in these cases. As I mull over the options, I am dis heartened by the knowledge that whether I use or withdraw anti biotics (asking the team to ob serve the patient closely) or re quest more testing, I may simply be deferring the tough decisions for another day. The list is revised every 2 years by a WHO expert committee. Medicines are designated as es sential on the basis of their effi cacy and safety, availability, ease of use in various settings, compar ative costeffectiveness, and pub lic health need. In many coun tries, the list forms the basis of national drug policies. Govern ments and health ministries often refer to it when making decisions regarding resource allocation and health care spending. The list does not include all efficacious medicines, the latest medicines, or even all medicines needed in a country. Rather, it helps to define the minimum medicine needs for a basic health system.
Although some protein con centrates (factors VIII and IX and immunoglobulins) are listed, no labile blood components are on the Model List. The reason for their absence is unclear. Certain ly, the lengthy, exhaustive process for applying for a listing can be discouraging: each component re quires a separate detailed, complex application. Most medicines are proposed by manufacturers with a commercial interest in having their products listed. There has been no similar advocacy for blood components that are collected and prepared by notforprofit organi zations, until now.
There are compelling reasons to add whole blood and redcell concentrates to the list. Blood transfusion originated as a medi cal practice requiring either sur gical intervention to join donor to recipient or a licensed practitioner to draw and immediately infuse
